Literature DB >> 27408388

Ascites as a Manifestation of GVHD: a Rare Phenomenon.

Bhausaheb Bagal1, Mukta Ramadwar2, Navin Khattry1.   

Abstract

Graft versus host disease (GVHD) usually have involvement of classical target organs. Manifestations of Chronic GVHD (cGVHD) are much more protean than acute GVHD. NIH consensus criterion for cGVHD proposes different diagnostic and distinctive features of cGVHD. It acknowledges certain uncommon manifestations that can be attributed to cGVHD only when they are associated with more specific features. Patients rarely may develop such manifestations which are not diagnostic of cGVHD themselves. In the absence of more specific features of cGVHD, they may pose diagnostic challenge. Amongst the rare reported manifestations of cGVHD is serositis manifesting as pleural effusion, pericardial effusion or ascites. We report two patients developing ascites as an isolated manifestation of cGVHD.

Entities:  

Keywords:  Allogeneic Transplantation; Ascites; Graft versus Host Disease; Serositis

Year:  2014        PMID: 27408388      PMCID: PMC4925472          DOI: 10.1007/s12288-014-0477-y

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  6 in total

1.  Pericardial effusion following conditioning for bone marrow transplantation in acute leukaemia.

Authors:  P A Veys; R McAvinchey; M T Rothman; G H Mair; A C Newland
Journal:  Bone Marrow Transplant       Date:  1987-08       Impact factor: 5.483

2.  Massive pericardial and pleural effusion with anasarca following allogeneic bone marrow transplantation.

Authors:  T Ueda; A Manabe; A Kikuchi; H Yoshino; Y Ebihara; T Ishii; H Yagasaki; T Mitsui; H Hisakawa; A Masunaga; K Tsuji; T Nakahata
Journal:  Int J Hematol       Date:  2000-06       Impact factor: 2.490

3.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  Massive pericardial effusion complicating the course of chronic graft-versus-host disease (cGVHD) in a child with acute lymphoblastic leukemia following allogeneic bone marrow transplantation.

Authors:  A Toren; A Nagler
Journal:  Bone Marrow Transplant       Date:  1997-11       Impact factor: 5.483

Review 5.  Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease.

Authors:  A Seber; S P Khan; J H Kersey
Journal:  Bone Marrow Transplant       Date:  1996-02       Impact factor: 5.483

6.  Massive ascites of donor T-cell origin in a patient with acute GVHD after a reduced-intensity allograft for CLL.

Authors:  V Ivanov; C Faucher; K Bilger; N Vey; D Sainty; B Calmels; C Chabannon; M Lafage-Pochitaloff; M J Mozziconacci; M Mohty; M A Chrestian; D Blaise
Journal:  Bone Marrow Transplant       Date:  2003-11       Impact factor: 5.483

  6 in total
  1 in total

1.  Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity.

Authors:  Ankur Varma; Susan C Abraham; Rohtesh S Mehta; Neeraj Y Saini; Medhavi Honhar; Munazza Rashid; Julianne Chen; Samer A Srour; Qaiser Bashir; Gabriela Rondon; Betul Oran; Chitra M Hosing; Yago Nieto; Partow Kebriaei; Amin M Alousi; Sairah Ahmed; David Marin; Issa F Khouri; Stefan O Ciurea; Muzaffar H Qazilbash; Katy Rezvani; Paolo Anderlini; Borje S Andersson; Elizabeth J Shpall; Richard E Champlin; Uday R Popat
Journal:  Blood Adv       Date:  2020-04-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.